Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Invenra Inc.

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development
From Invenra Inc.
Via Business Wire
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
From Invenra Inc.
Via Business Wire
Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors
From Invenra Inc.
Via Business Wire
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
From Invenra Inc.
Via Business Wire
Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
From Invenra Inc.
Via Business Wire
Invenra Unveils Rapid Bispecific Antibody Discovery Services – 4 Months from Start to Finish
From Invenra Inc.
Via Business Wire
Invenra Welcomes Three Industry Leaders to Its Board of Directors
From Invenra Inc.
Via Business Wire
Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment
From Invenra Inc.
Via Business Wire
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery
From Invenra Inc.
Via Business Wire
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
From Invenra Inc.
Via Business Wire
Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter
From Invenra Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.